Back to top

Image: Shutterstock

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna

Read MoreHide Full Article

For Immediate Release

Chicago, IL – May 1, 2020 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Gilead Sciences, Inc. (GILD - Free Report) , Pfizer, Inc. (PFE - Free Report) , Sanofi (SNY - Free Report) , GlaxoSmithKline plc (GSK - Free Report) and Moderna, Inc. (MRNA - Free Report) .

Here are highlights from Thursday’s Analyst Blog:

Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat

Gilead Sciences, Inc. on Apr 29 said that preliminary results of its experimental coronavirus candidate remdesivir’s trial showed optimistic results. At least 50% of the patients administered with the drug showed improvement, while more than half were cured and discharged from the hospital within two weeks. Following this development, White House health advisor Dr. Anthony Fauci said that the drug trial testing brought “quite good news” and sets a new standard of treatment for COVID-19 patients.

Gilead’s shares rallied on the news, closing the day up 5.7%. A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives. Also, pharmaceutical giants are going for partnerships to speed up development of a vaccine for the novel coronavirus.

Gilead Shows the Way

Gilead Sciences said that preliminary results of its COVID-19 drug trial showed half of the patients with five-day dosage of the antiviral drug improved over the days. The remaining 50% were cured and discharged from the hospital within two weeks.

The study was carried out on two groups of patients severely affected by COVID-19. The first group received a five-day dosage of remdesivir, while the second group was administered a 10-day dosage of the drug. Of the total patients discharged, 64.5% belonged to the first group, while 53.8% were from the second group. Gilead has a Zacks Rank #3 (Hold). The company’s shares have gained 14.1% over the past 30 days.

Preliminary results from a U.S. government trial also showed that patients administered remdesivir recovered 31% faster than those given a placebo. A number of studies are ongoing to test if remdesivir is effective in stopping the virus from replicating.

Biotech Companies Speed Up R&D

A number of drugmakers and biotech companies are initiating development of drugs, vaccine and therapies to get a grip over the fast-spreading virus. Substantial progress has been made over the past month, with many pharmaceuticalcompanies coming up with impressive reports.

Earlier this week, German pharmaceutical giant Pfizer, Inc. said that a coronavirus vaccine could be ready for emergency use as early as September. The companies said that they have begun human trials of the potential vaccine, BNT162, on Apr 23 in Germany. Pfizer carries a Zacks #3. Pfizer’s shares have gained 23.4% in the past month.

Sanofi and GlaxoSmithKline plc have also joined forces to expedite the development of a vaccine for the Wuhan virus. Sanofi recently said that if successful, the vaccine would be available in the second half of 2021. Sanofi carries a Zacks Rank #2 (Buy), while GlaxoSmithKline has a Zacks Rank #3. Shares of Sanofi have gained 15.5% in the past one month. GlaxoSmithKline’s shares have jumped 14.8% over the past 30 days. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Also, Moderna, Inc. recently announced that it has begun a phase 1 trial of a COVID-19 vaccine candidate, enrolling subjects at the highest dose. Moderna sports a Zacks Rank #1.

Today’s Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                            

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.